The stock of Jaguar Health Inc (JAGX) has seen a -27.03% decrease in the past week, with a -51.74% drop in the past month, and a -56.22% decrease in the past quarter. The volatility ratio for the week is 5.84%, and the volatility levels for the past 30 days are at 8.31% for JAGX. The simple moving average for the past 20 days is -30.19% for JAGX’s stock, with a -85.02% simple moving average for the past 200 days.
Is It Worth Investing in Jaguar Health Inc (NASDAQ: JAGX) Right Now?
The 36-month beta value for JAGX is at 0.70. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for JAGX is 1.04M, and currently, shorts hold a 2.77% of that float. The average trading volume for JAGX on June 20, 2025 was 139.97K shares.
JAGX) stock’s latest price update
The stock of Jaguar Health Inc (NASDAQ: JAGX) has decreased by -14.06 when compared to last closing price of 3.23. Despite this, the company has experienced a -27.03% fall in its stock price over the last five trading sessions. accessnewswire.com reported 2025-06-17 that Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company’s founder, president and CEO, will present virtually on Wednesday, June 18, 2025 at the Emerging Growth Conference. Participation Instructions for Jaguar’s Virtual Presentation at the Emerging Growth Conference When: Wednesday, June 18, 2025 from 9:40 – 10:10 AM Eastern Time Where: Online (Click Here) Registration link for conference: Click Here Replay: An archived webcast of the presentation will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.
Analysts’ Opinion of JAGX
Many brokerage firms have already submitted their reports for JAGX stocks, with Cantor Fitzgerald repeating the rating for JAGX by listing it as a “Overweight.” The predicted price for JAGX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on July 07, 2021 of the previous year 2021.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see JAGX reach a price target of $2. The rating they have provided for JAGX stocks is “Buy” according to the report published on July 11th, 2017.
JAGX Trading at -55.60% from the 50-Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.49% of loss for the given period.
Stock Fundamentals for JAGX
Current profitability levels for the company are sitting at:
- -2.78 for the present operating margin
- 0.82 for the gross margin
The net margin for Jaguar Health Inc stands at -3.45. The total capital return value is set at -1.38. Equity return is now at value -423.79, with -74.37 for asset returns.
Based on Jaguar Health Inc (JAGX), the company’s capital structure generated 0.98 points at debt to capital in total, while cash flow to debt ratio is standing at -0.77. The debt to equity ratio resting at 46.19. The interest coverage ratio of the stock is -572.09.
Currently, EBITDA for the company is -36.66 million with net debt to EBITDA at -0.85. When we switch over and look at the enterprise to sales, we see a ratio of 3.14. The receivables turnover for the company is 9.41for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.08.
Conclusion
In conclusion, Jaguar Health Inc (JAGX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
